Advanced solid tumor
Conditions
Interventions
lung cancer Group:According to the study protocol
colorectal cancer group:According to the study protocol
esophageal cancer group:According to the study protocol
liver cancer group:According to the study protocol
Gynecological tumor group:According to the study protocol
mammary cancer group:According to the study protocol
renal carcinoma group:According to the study protocol
Other advanced solid tumors group:According to the study protocol
Sponsors
People's Hospital of Ruyang County
Eligibility
Sex/Gender
All
Age
12 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. The patient voluntarily participated in this study, signed an informed consent form, had good compliance, and cooperated with the follow-up; 2. Aged 12-85 years, no gender limit; 3. Diagnosed as malignant tumor by histopathology and immunohistochemical examination; 4. PS = 12 weeks 6. Patients with advanced solid tumors diagnosed pathologically, regardless of the type of cancer, have at least one measurable lesion; 7. There are no serious uncontrollable metabolic aspects, infections or neurological diseases; 8. Excluding other malignant tumors.
Exclusion criteria
Exclusion criteria: 1. Those who have been confirmed to be allergic to Anlotinib Hydrochloride and/or its excipients; 2. Suffering from uncontrollable hypertension (systolic blood pressure> 140mmHg, diastolic blood pressure> 90mmHg, despite the best medical treatment), suffering from myocardial ischemia or myocardial infarction above grade II, poorly controlled arrhythmias (including QTc (Male >=450ms, female >=470ms); according to NYHA standards, grade III-IV cardiac insufficiency, or cardiac color Doppler ultrasound examination revealed left ventricular ejection fraction (LVEF) 1.5, APTT>1.5ULN), with bleeding tendency; 5. There are many factors that affect the absorption of oral drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.); 6. Patients whose tumors have invaded important blood vessels or the investigator judges that hemorrhage may occur during the follow-up study; 7. Pregnant or lactating women; 8. Infectious wounds prolonged and unhealed; 9. According to the investigator's judgment, patients with concomitant diseases that seriously endanger the safety of the patient or affect the patient's completion of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Disease control rate;Quality of Life;Overall survival; | — |
Countries
China
Contacts
Public ContactWu Yongfei
People's Hospital of Ruyang County
Outcome results
None listed